摘要
目的：探讨采用替勃龙治疗绝经后妇女乳腺增生的临床疗效。方法：采用随机数字表法将太原市武警医院内分泌科2013年1月-2015年1月收治的140例绝经后乳腺增生妇女分为替勃龙组和常规治疗组各70例,常规组采用谷维素片口服治疗,替勃龙组加用替勃龙（1.25 mg/次,1次/日）治疗,比较两组患者治疗6个月后的疗效差异。结果：治疗前两组患者的疼痛评分差异不显著（P〉0.05）,治疗后替勃龙组患者的疼痛评分显著低于常规组（P〈0.05）,两组较治疗前均显著的降低（P〈0.05）。治疗前两组患者的乳腺导管直径差异不显著（P〉0.05）,治疗后替勃龙组患者的乳腺导管直径显著低于常规组（P〈0.05）,两组较治疗前均显著的降低（P〈0.05）。治疗前后两组患者的雌激素与血脂水平在组内与组间比较,差异均无统计学意义（P〉0.05）。替勃龙组治疗6个月后的临床有效率显著高于常规组（P〈0.05）。结论：替勃龙治疗绝经后妇女乳腺增生具有显著的临床效果,同时不会影响患雌激素及脂质代谢,具有较好的安全性。
Objective： To explore the clinical efficacy of tibolone in treatment of breast hyperplasia among postmenopansal women. Methods： A total of 140 postmenopausal women with breast hyperplasia treated in department of endocrinology in the hospital from January 2013 to January 2015 were selected and divided into tibolone group and routine treatment group according to random number table, 70 women in each group, the women in routine treatment group were treated with oral administration of oryzanol tablets, while the women in tibolone group were treated with oryzanol tablets combined with tibolone （ 1.25 mg per time, once a day） ; the curative effects at six months after treatment in the two groups were compared. Results： There was no statistically significant difference in pain score before treatment between the two groups （P〉0.05）, after treatment, pain score in tibolone group was statistically significantly lower than that in routine treatment group （P〈0. 05 ）, compared with before treatment, pain scores in the two groups decreased significantly （P〈0.05） . Before treatment, there was no statistically significant difference in the diameter of mammary ducts between the two groups （ P〉0. 05 ）, after treatment, the diameter of mammary ducts in tibolone group was statistically significantly shorter than that in routine treatment group （P〈0. 05）, compared with before treatment, the diameter of mammary ducts in the two groups decreased significantly （P〈0. 05 ） . Before and after treatment, there was no statistically significant difference in estrogen and blood lipid levels between the two groups （ P〉0. 05 ） . The clinical effective rate in tibolone group at six months after treatment was statistically significantly higher than that in routine treatment group （P〈0. 05 ） . Conclusion： The clinical efficacy of tibolone in treatment of breast hyperplasia among postmenopausal women is significant, tibolone does not affect estrogen and lipid metabolism, and the safety is good.
出处
《中国妇幼保健》
CAS
2015年第13期2025-2027,共3页
Maternal and Child Health Care of China
基金
山西省科学技术项目基金项目编号〔2013ST72823〕
关键词
替勃龙
绝经后
乳腺增生
临床疗效
Tibolone
Postmenopause
Breast hyperplasia
Chnical efficacy
